Mandate

Vinge advises international private equity firm Cinven on the acquisition of Envirotainer

July 12, 2018 M&A

Headquartered in Stockholm, Envirotainer designs, manufactures and leases active temperature-controlled containers used primarily for air freighting biopharma products, transporting up to two millions doses of medicine per day. Envirotainer serves c. 600 customers worldwide, including many of the blue-chip global biopharma companies.

With c. 300 employees, Envirotainer operates from regional centres in Stockholm, Frankfurt, Dallas and Singapore, with a portfolio of more than 5,500 leased containers globally. Envirotainer developed and marketed the first container with an active temperature control system in 1995 and since then has significantly invested in technology and its container fleet.

Vinge’s team consisted of partners Christina Kokko and Kristina Ekberg (M&A), Louise Brorsson Salomon and Albert Wållgren (Banking and Finance) together with associates Filip Öhrner, Samra Baytar, Karl Klackenberg, Anna Thoms, Vilhelm Rondahl and Arvid Axelryd (M&A), Linn Adelwald and Agnes Perbo (Banking and Finance), Hedvig Ekdahl, Lisa Hörnqvist and Hayaat Ibrahim (Commercial Agreements), Klara Secher (IP), Sara Strandberg and Sophia Holm (Employment), Johan Cederblad (Environment), Frida Ställborn (Real Estate) and VDR assistant Jessica Öijer.

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026